Microrna and Gynecological Cancers: Focus on Mir-195 Publisher Pubmed



Davoodvandi A^{1, 2} ; Rafiyan M² ; Mansournia MA³ ; Rajabpoor Nikoo N⁴ ; Saati M⁵ ; Samimi M⁶ ; Asemi Z²
Source: Pathology Research and Practice Published:2023

Abstract

Different cancer types have been shown to have down-regulated expression levels of miR-195 as an anti-tumor agent. MiR-195 family members can inhibit cancer cell proliferation, angiogenesis, epithelial-mesenchymal transition and metastases, immunosuppression, glycolysis, drug resistance, and cancer stem cell development by targeting the 3′-UTR of the mRNA of different pro-tumor genes. MiR-195 identified as a tumor suppressor miR in a variety of cancers, most notably gynecological malignancies such as cervical, endometrial, and ovarian carcinoma. As a result, restoring miR-195 expression should be regarded as a potential therapy for either prevention or treatment of gynecological cancers. This review will present the most recent data about miR-195-mediated anti-tumor effects in gynecological malignancies, emphasizing its downstream signaling pathways and target genes, as well as prospective treatment techniques. © 2023 Elsevier GmbH